- ►diabetesjournals.org S Madsbad, O Schmitz, J Ranstam, G … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A double-blind, randomized, parallel-group,
placebo-controlled trial with an open-label comparator arm was conducted among
193 outpatients with type 2 diabetes. The mean age was 56.6 years and the ... Cited by 170 - Related articles - BL Direct - All 6 versions
- Free from Publisher H Harder, L Nielsen, TDT Thi, A Astrup - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—After 8 weeks, liraglutide reduced fasting serum glucose (liraglutide,
−1.90 mmol/l, and placebo, 0.27 mmol/l; P = 0.002) and HbA 1c (liraglutide,
−0.33%, and placebo, 0.47%; P = 0.028) compared with placebo. No change ... Cited by 90 - Related articles - BL Direct - All 7 versions
MN Feinglos, MF Saad, FX Pi-Sunyer, B An, O … - Diabetic Medicine, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 65 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org KB Degn, CB Juhl, J Sturis, G Jakobsen, B … - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for
treating type 2 diabetes. We explored the effect of short-term (1 week)
treatment with a GLP-1 derivative, liraglutide (NN2211), on 24-h dynamics ... Cited by 168 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org JB Buse, RR Henry, J Han, DD Kim, MS … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—At week 30, HbA 1c changes from baseline were −0.86 ± 0.11, −0.46
± 0.12, and 0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms,
respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA ... Cited by 454 - Related articles - BL Direct - All 13 versions
FD Care - members.medscape.com Liraglutide is a long-acting, acylated GLP-1 analog, acting as a full agonist
toward the GLP-1 receptor. [15] Studies in animals and humans have demonstrated
promising blood glucose-lowering effects as well as a favorable safety ... Related articles - All 3 versions
MA Nauck, M Hompesch, R Filipczak, TD Le, M … - Experimental and clinical endocrinology & diabetes: …, 2006 - ncbi.nlm.nih.gov AIMS: Effects of the long acting GLP-1 analogue--liraglutide in subjects with
type 2 diabetes. METHODS: 144 type 2 diabetic subjects on metformin treatment
(1000 mg BID) were randomised to 5 weeks of treatment (double-blind) with ... Cited by 59 - Related articles - BL Direct - All 5 versions
CB Juhl, M Hollingdal, J Sturis, G Jakobsen, H … - Diabetes, 2002 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential
interest for the treatment of type 2 diabetes. To evaluate actions of NN2211, a
long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, ... Cited by 174 - Related articles - BL Direct - All 6 versions
- ►pubget.com [PDF] H Agersø, LB Jensen, B Elbrønd, P Rolan, M … - Diabetologia, 2002 - Springer Aims/hypothesis. Glucagon-like peptide-1 (GLP-1), a polypeptide hormone secreted
by the l-cells in the gastrointestinal tract, has shown promising effects as a
new treatment modality for patients with Type II (non-insulin-dependent) ... Cited by 167 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org B Elbrønd, G Jakobsen, S Larsen, H Agersø, … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a double-blind, randomized dose, escalation,
placebo-controlled study, healthy male subjects were enrolled at eight
consecutive dose levels (1.25, 2.5, 5.0, 10.0, 12.5, 15.0, 17.5, and 20.0 ... Cited by 103 - Related articles - BL Direct - All 6 versions
